参考文献/References:
[1] Conte G,Schotten U,Auricchio A. The atrial phenotype of the inherited primary arrhythmia syndromes[J]. Arrhythm Electrophysiol Rev,2019,8(1):42-46.
[2] Roselli C,Chaffin MD,Weng LC,et al. Multi-ethnic genome-wide association study for atrial fibrillation[J]. Nat Genet,2018,50(9):1225-1233.
[3] Go AS,Hylek EM,Phillips KA,et al. Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA) Study[J]. JAMA,2001,285(18):2370-2375.
[4] Johnson JN,Tester DJ,Perry J,et al. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome[J]. Heart Rhythm,2008,5(5):704-709.
[5] Giustetto C,di Monte F,Wolpert C,et al. Short QT syndrome:clinical findings and diagnostic-therapeutic implications[J]. Eur Heart J,2006,27(20):2440-2447.
[6] El-Sherif N,Turitto G,Boutjdir M. Congenital long QT syndrome and torsade de pointes[J]. Ann Noninvasive Electrocardiol,2017,22(6):e12481.
[7] Kirchhof P,Eckardt L,Franz MR,et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome[J]. J Cardiovasc Electrophysiol,2003,14(10):1027-1033.
[8] Satoh T,Zipes DP. Cesium-induced atrial tachycardia degenerating into atrial fibrillation in dogs:atrial torsades de pointes?[J]. J Cardiovasc Electrophysiol,1998,9(9):970-975.
[9] Bellocq C,van Ginneken AC,Bezzina CR,et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome[J]. Circulation,2004,109(20):2394-2397.
[10] Deo M,Ruan Y,Pandit SV,et al. KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia[J]. Proc Natl Acad Sci U S A,2013,110(11):4291-4296.
[11] Villafa?e J,Fischbach P,Gebauer R. Short QT syndrome manifesting with neonatal atrial fibrillation and bradycardia[J]. Cardiology,2014,128(3):236-240.
[12] Kusano KF,Taniyama M,Nakamura K,et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation,electrophysiology,and clinical backgrounds[J]. J Am Coll Cardiol,2008,51(12):1169-1175.
[13] Conte G,Sieira J,Ciconte G,et al. Implantable cardioverter-defibrillator therapy in Brugada syndrome:a 20-year single-centre experience[J]. J Am Coll Cardiol,2015,65(9):879-888.
[14] Hasdemir C,Payzin S,Kocabas U,et al. High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia[J]. Heart Rhythm,2015,12(7):1584-1594.
[15] Junttila MJ,Tikkanen JT,Kentt? T,et al. Early repolarization as a predictor of arrhythmic and nonarrhythmic cardiac events in middle-aged subjects[J]. Heart Rhythm,2014,11(10):1701-1706.
[16] Shan J,Xie W,Betzenhauser M,et al. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia[J]. Circ Res,2012,111(6):708-717.
[17] Magnani JW,Williamson MA,Ellinor PT,et al. P wave indices:current status and future directions in epidemiology,clinical,and research applications[J]. Circ Arrhythm Electrophysiol,2009,2(1):72-79.
[18] Conte G,Caputo ML,Volders PGA,et al. Concealed abnormal atrial phenotype in patients with Brugada syndrome and no history of atrial fibrillation[J]. Int J Cardiol,2018,253:66-70.